Výsledky vyhledávání

Zobrazeno 1 - 10 of 582 pro vyhledávání: '"Muntión S"'

Řazení

Vybrat vše | Vybrané výsledky:

Vybrat výsledek číslo 1 1

Editorial & Opinion

Targeting NOX2 and glycolytic metabolism as a therapeutic strategy in acute myeloid leukaemia.

Autor: Ijurko C; Departamento de Bioquímica y Biología Molecular, Universidad de Salamanca, Plaza Doctores de la Reina, s/n, Salamanca, 37007, Spain.; IBSAL (Instituto de Investigación Biomédica de Salamanca), Salamanca, 37007, Spain., Romo-González M; Departamento de Bioquímica y Biología Molecular, Universidad de Salamanca, Plaza Doctores de la Reina, s/n, Salamanca, 37007, Spain.; IBSAL (Instituto de Investigación Biomédica de Salamanca), Salamanca, 37007, Spain.; Present Address: Susan Lehman Cullman Laboratory for Cancer Research, Rutgers University, Piscataway, NJ, 08854, USA., Prieto-Bermejo R; Departamento de Bioquímica y Biología Molecular, Universidad de Salamanca, Plaza Doctores de la Reina, s/n, Salamanca, 37007, Spain.; IBSAL (Instituto de Investigación Biomédica de Salamanca), Salamanca, 37007, Spain.; Present Address: Rutgers Cancer Institute, Rutgers University, New Brunswick, NJ, 08901, USA., Díez-Campelo M; IBSAL (Instituto de Investigación Biomédica de Salamanca), Salamanca, 37007, Spain.; Servicio de Hematología, Hospital Universitario de Salamanca, Salamanca, Spain.; Departamento de Medicina, Universidad de Salamanca, Salamanca, 37007, Spain., Vidriales MB; IBSAL (Instituto de Investigación Biomédica de Salamanca), Salamanca, 37007, Spain.; Servicio de Hematología, Hospital Universitario de Salamanca, Salamanca, Spain., Muntión S; IBSAL (Instituto de Investigación Biomédica de Salamanca), Salamanca, 37007, Spain.; Servicio de Hematología, Hospital Universitario de Salamanca, Salamanca, Spain., Sánchez-Guijo F; IBSAL (Instituto de Investigación Biomédica de Salamanca), Salamanca, 37007, Spain.; Servicio de Hematología, Hospital Universitario de Salamanca, Salamanca, Spain.; Departamento de Medicina, Universidad de Salamanca, Salamanca, 37007, Spain., Sánchez-Yagüe J; Departamento de Bioquímica y Biología Molecular, Universidad de Salamanca, Plaza Doctores de la Reina, s/n, Salamanca, 37007, Spain.; IBSAL (Instituto de Investigación Biomédica de Salamanca), Salamanca, 37007, Spain., Hernández-Hernández Á; Departamento de Bioquímica y Biología Molecular, Universidad de Salamanca, Plaza Doctores de la Reina, s/n, Salamanca, 37007, Spain. angelhh@usal.es.; IBSAL (Instituto de Investigación Biomédica de Salamanca), Salamanca, 37007, Spain. angelhh@usal.es.

Publikováno v: Biomarker research [Biomark Res] 2024 Oct 29; Vol. 12 (1), pp. 128. Date of Electronic Publication: 2024 Oct 29.

Zobrazit plný text záznamu

Vybrat výsledek číslo 2 2

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vybrat výsledek číslo 3 3

Akademický článek

Effects of Dietary Supplementation with a Ferulic Acid-Rich Bioactive Component of Wheat Bran in a Murine Model of Graft-Versus-Host Disease.

Autor: Preciado S; Cell Therapy Unit, Hematology Department, University Hospital of Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), University of Salamanca, 37007 Salamanca, Spain.; RICORS TERAV, ISCIII, 28029 Madrid, Spain.; Centro en Red de Medicina Regenerativa y Terapia Celular de Castilla y León, 37007 Salamanca, Spain., Martínez-Villaluenga C; Institute of Food Science, Technology and Nutrition (ICTAN-CSIC), José Antonio Novais 10, 28040 Madrid, Spain., Rico D; Agrarian Technological Institute of Castilla and Leon (ITACyL), Ctra. Burgos Km 119, Finca Zamadueñas, 47071 Valladolid, Spain., Muntión S; Cell Therapy Unit, Hematology Department, University Hospital of Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), University of Salamanca, 37007 Salamanca, Spain.; RICORS TERAV, ISCIII, 28029 Madrid, Spain.; Centro en Red de Medicina Regenerativa y Terapia Celular de Castilla y León, 37007 Salamanca, Spain., García-Macías MC; Department of Medicine and Cancer Research Center, University of Salamanca, 37007 Salamanca, Spain., Navarro-Bailón A; Cell Therapy Unit, Hematology Department, University Hospital of Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), University of Salamanca, 37007 Salamanca, Spain.; RICORS TERAV, ISCIII, 28029 Madrid, Spain.; Centro en Red de Medicina Regenerativa y Terapia Celular de Castilla y León, 37007 Salamanca, Spain., Martín-Diana AB; Agrarian Technological Institute of Castilla and Leon (ITACyL), Ctra. Burgos Km 119, Finca Zamadueñas, 47071 Valladolid, Spain., Sánchez-Guijo F; Cell Therapy Unit, Hematology Department, University Hospital of Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), University of Salamanca, 37007 Salamanca, Spain.; RICORS TERAV, ISCIII, 28029 Madrid, Spain.; Centro en Red de Medicina Regenerativa y Terapia Celular de Castilla y León, 37007 Salamanca, Spain.

Publikováno v: Nutrients [Nutrients] 2023 Oct 28; Vol. 15 (21). Date of Electronic Publication: 2023 Oct 28.

Zobrazit plný text záznamu

Vybrat výsledek číslo 4 4

Co-administration of human MSC overexpressing HIF-1a increases human CD34(+) cell engraftment in vivo

Autor: Preciado S, Sirerol-Piquer MS, Muntión S, Osugui L, Martí-Chillón GJ, Navarro-Bailón A, Sepúlveda P, Sánchez-Guijo F

Publikováno v: STEM CELL RESEARCH & THERAPY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

BACKGROUND: Poor graft function or graft failure after allogeneic stem cell transplantation is an unmet medical need, in which mesenchymal stromal cells (MSC) constitute an attractive potential therapeutic approach. Hypoxia-inducible factor-1a (HIF-1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::e213817e98083e2d8f3c84cc5473275e
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=15277

Zobrazit plný text záznamu

Vybrat výsledek číslo 5 5

Akademický článek

Therapeutic potential of mesenchymal stromal/stem cells in critical-care patients with systemic inflammatory response syndrome.

Autor: Martí-Chillón GJ; IBSAL-University Hospital of Salamanca, Salamanca, Spain.; Department of Medicine, University of Salamanca, Salamanca, Spain., Muntión S; IBSAL-University Hospital of Salamanca, Salamanca, Spain.; RICORS TERAV, ISCIII, Madrid, Spain.; Regenerative Medicine and Cellular Therapy Network Center of Castilla y León, Salamanca, Spain., Preciado S; IBSAL-University Hospital of Salamanca, Salamanca, Spain.; RICORS TERAV, ISCIII, Madrid, Spain.; Regenerative Medicine and Cellular Therapy Network Center of Castilla y León, Salamanca, Spain., Osugui L; IBSAL-University Hospital of Salamanca, Salamanca, Spain.; Regenerative Medicine and Cellular Therapy Network Center of Castilla y León, Salamanca, Spain., Navarro-Bailón A; IBSAL-University Hospital of Salamanca, Salamanca, Spain.; RICORS TERAV, ISCIII, Madrid, Spain.; Regenerative Medicine and Cellular Therapy Network Center of Castilla y León, Salamanca, Spain., González-Robledo J; IBSAL-University Hospital of Salamanca, Salamanca, Spain.; Department of Medicine, University of Salamanca, Salamanca, Spain., Sagredo V; IBSAL-University Hospital of Salamanca, Salamanca, Spain., Blanco JF; IBSAL-University Hospital of Salamanca, Salamanca, Spain.; Regenerative Medicine and Cellular Therapy Network Center of Castilla y León, Salamanca, Spain.; Department of Surgery, University of Salamanca, Salamanca, Spain., Sánchez-Guijo F; IBSAL-University Hospital of Salamanca, Salamanca, Spain.; Department of Medicine, University of Salamanca, Salamanca, Spain.; RICORS TERAV, ISCIII, Madrid, Spain.; Regenerative Medicine and Cellular Therapy Network Center of Castilla y León, Salamanca, Spain.

Publikováno v: Clinical and translational medicine [Clin Transl Med] 2023 Jan; Vol. 13 (1), pp. e1163.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Vybrat výsledek číslo 6 6

Akademický článek

Eltrombopag increases the hematopoietic supporting ability of mesenchymal stem/stromal cells.

Autor: Muntión S; Cell Therapy Area, Department of Hematology, Institute of Biomedical Research of Salamanca-Hospital Universitario de Salamanca (IBSAL-HUS), Paseo de San Vicente 58-182, 37007 Salamanca, Spain.; RICORS TERAV, ISCIII, Madrid, Spain.; Centro en Red de Medicina Regenerativa y Terapia Celular de Castilla y León, Valladolid, Spain., Preciado S; Cell Therapy Area, Department of Hematology, Institute of Biomedical Research of Salamanca-Hospital Universitario de Salamanca (IBSAL-HUS), Salamanca, Spain.; RICORS TERAV, ISCIII, Madrid, Spain.; Centro en Red de Medicina Regenerativa y Terapia Celular de Castilla y León, Valladolid, Spain., Sánchez-Luis E; Bioinformatics and Functional Genomics Group, Cancer Research Center (CiC-IBMCC), Consejo Superior de Investigaciones Científicas (CSIC) and University of Salamanca (USAL), Salamanca, Spain., Corchete L; Institute of Biomedical Research of Salamanca (IBSAL), Cancer Research Center (CiC-IBMCC, CSIC/USAL), Center for Biomedical Research in Network of Cancer (CIBERONC), Hematology Department, University Hospital of Salamanca, Salamanca, Spain., Díez-Campelo M; RICORS TERAV, ISCIII, Madrid, Spain.; Center for Biomedical Research in Network of Cancer (CIBERONC), Department of Hematology, University Hospital of Salamanca (IBSAL-HUS), Salamanca, Spain.; Department of Medicine, University of Salamanca (USAL), Salamanca, Spain., Osugui L; Cell Therapy Area, Department of Hematology, Institute of Biomedical Research of Salamanca-Hospital Universitario de Salamanca (IBSAL-HUS), Salamanca, Spain.; Centro en Red de Medicina Regenerativa y Terapia Celular de Castilla y León, Valladolid, Spain., Martí-Chillón GJ; Cell Therapy Area, Department of Hematology, Institute of Biomedical Research of Salamanca-Hospital Universitario de Salamanca (IBSAL-HUS), Salamanca, Spain.; Centro en Red de Medicina Regenerativa y Terapia Celular de Castilla y León, Valladolid, Spain., Vidriales MB; Center for Biomedical Research in Network of Cancer (CIBERONC), Department of Hematology, University Hospital of Salamanca (IBSAL-HUS), Salamanca, Spain., Navarro-Bailón A; Cell Therapy Area, Department of Hematology, Institute of Biomedical Research of Salamanca-Hospital Universitario de Salamanca (IBSAL-HUS), Salamanca, Spain.; RICORS TERAV, ISCIII, Madrid, Spain.; Centro en Red de Medicina Regenerativa y Terapia Celular de Castilla y León, Valladolid, Spain., De Las Rivas J; Bioinformatics and Functional Genomics Group, Cancer Research Center (CiC-IBMCC), Consejo Superior de Investigaciones Científicas (CSIC) and University of Salamanca (USAL), Salamanca, Spain., Sánchez-Guijo F; Cell Therapy Area, Department of Hematology, Institute of Biomedical Research of Salamanca-Hospital Universitario de Salamanca (IBSAL-HUS), Salamanca, Spain.; RICORS TERAV, ISCIII, Madrid, Spain.; Centro en Red de Medicina Regenerativa y Terapia Celular de Castilla y León, Valladolid, Spain.; Center for Biomedical Research in Network of Cancer (CIBERONC), Department of Hematology, University Hospital of Salamanca (IBSAL-HUS), Salamanca, Spain.; Department of Medicine, University of Salamanca (USAL), Salamanca, Spain.

Publikováno v: Therapeutic advances in hematology [Ther Adv Hematol] 2022 Dec 26; Vol. 13, pp. 20406207221142137. Date of Electronic Publication: 2022 Dec 26 (Print Publication: 2022).

Zobrazit plný text záznamu

Vybrat výsledek číslo 7 7

Akademický článek

Mesenchymal Stromal Cells Combined With Elastin-Like Recombinamers Increase Angiogenesis In Vivo After Hindlimb Ischemia.

Autor: Ibáñez-Fonseca A; BIOFORGE Lab, University of Valladolid, CIBER-BBN, Valladolid, Spain., Rico A; Cell Therapy Unit, Hematology Department, University Hospital of Salamanca, Salamanca, Spain., Preciado S; Cell Therapy Unit, Hematology Department, University Hospital of Salamanca, Salamanca, Spain.; RICORS TERAV, ISCIII, Madrid, Spain.; Centro en Red de Medicina Regenerativa y Terapia Celular de Castilla y León, Salamanca, Spain.; Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain.; Department of Medicine and Cancer Research Center, University of Salamanca, Salamanca, Spain., González-Pérez F; BIOFORGE Lab, University of Valladolid, CIBER-BBN, Valladolid, Spain., Muntión S; Cell Therapy Unit, Hematology Department, University Hospital of Salamanca, Salamanca, Spain.; RICORS TERAV, ISCIII, Madrid, Spain.; Centro en Red de Medicina Regenerativa y Terapia Celular de Castilla y León, Salamanca, Spain.; Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain.; Department of Medicine and Cancer Research Center, University of Salamanca, Salamanca, Spain., García-Briñón J; Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain.; Departamento de Biología Celular y Patología, Facultad de Medicina, Salamanca, Spain., García-Macías MC; Department of Medicine and Cancer Research Center, University of Salamanca, Salamanca, Spain., Rodríguez-Cabello JC; BIOFORGE Lab, University of Valladolid, CIBER-BBN, Valladolid, Spain.; Centro en Red de Medicina Regenerativa y Terapia Celular de Castilla y León, Salamanca, Spain., Pericacho M; Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain.; Renal and Cardiovascular Research Unit, Department of Physiology and Pharmacology, University of Salamanca, Salamanca, Spain., Alonso M; BIOFORGE Lab, University of Valladolid, CIBER-BBN, Valladolid, Spain.; Centro en Red de Medicina Regenerativa y Terapia Celular de Castilla y León, Salamanca, Spain., Sánchez-Guijo F; Cell Therapy Unit, Hematology Department, University Hospital of Salamanca, Salamanca, Spain.; RICORS TERAV, ISCIII, Madrid, Spain.; Centro en Red de Medicina Regenerativa y Terapia Celular de Castilla y León, Salamanca, Spain.; Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain.; Department of Medicine and Cancer Research Center, University of Salamanca, Salamanca, Spain.

Publikováno v: Frontiers in bioengineering and biotechnology [Front Bioeng Biotechnol] 2022 Jun 23; Vol. 10, pp. 918602. Date of Electronic Publication: 2022 Jun 23 (Print Publication: 2022).

Zobrazit plný text záznamu

Vybrat výsledek číslo 8 8

Akademický článek

Co-administration of human MSC overexpressing HIF-1α increases human CD34 ⁺ cell engraftment in vivo.

Autor: Preciado S; Cell Therapy Unit, Hematology Department, University Hospital of Salamanca, IBSAL, University of Salamanca, Paseo de San Vicente 58-182, 37007, Salamanca, Spain.; RETIC TerCel, ISCIII, Madrid, Spain.; Centro en Red de Medicina Regenerativa y Terapia Celular de Castilla y León, Salamanca, Spain., Sirerol-Piquer MS; Departamento de Biología Celular, Biología Funcional y Antropología Física, University of Valencia, Burjassot, Spain.; Instituto de Biotecnología y Biomedicina (BioTecMed), University of Valencia, Burjassot, Spain.; RETIC TerCel, ISCIII, Madrid, Spain., Muntión S; Cell Therapy Unit, Hematology Department, University Hospital of Salamanca, IBSAL, University of Salamanca, Paseo de San Vicente 58-182, 37007, Salamanca, Spain.; RETIC TerCel, ISCIII, Madrid, Spain.; Centro en Red de Medicina Regenerativa y Terapia Celular de Castilla y León, Salamanca, Spain., Osugui L; Cell Therapy Unit, Hematology Department, University Hospital of Salamanca, IBSAL, University of Salamanca, Paseo de San Vicente 58-182, 37007, Salamanca, Spain.; RETIC TerCel, ISCIII, Madrid, Spain.; Centro en Red de Medicina Regenerativa y Terapia Celular de Castilla y León, Salamanca, Spain., Martí-Chillón GJ; Cell Therapy Unit, Hematology Department, University Hospital of Salamanca, IBSAL, University of Salamanca, Paseo de San Vicente 58-182, 37007, Salamanca, Spain.; RETIC TerCel, ISCIII, Madrid, Spain.; Centro en Red de Medicina Regenerativa y Terapia Celular de Castilla y León, Salamanca, Spain., Navarro-Bailón A; Cell Therapy Unit, Hematology Department, University Hospital of Salamanca, IBSAL, University of Salamanca, Paseo de San Vicente 58-182, 37007, Salamanca, Spain.; RETIC TerCel, ISCIII, Madrid, Spain.; Centro en Red de Medicina Regenerativa y Terapia Celular de Castilla y León, Salamanca, Spain., Sepúlveda P; Regenerative Medicine and Heart Transplantation Unit, Instituto de Investigación Sanitaria La Fe, Valencia, Spain.; RETIC TerCel, ISCIII, Madrid, Spain., Sánchez-Guijo F; Cell Therapy Unit, Hematology Department, University Hospital of Salamanca, IBSAL, University of Salamanca, Paseo de San Vicente 58-182, 37007, Salamanca, Spain. ferminsg@usal.es.; RETIC TerCel, ISCIII, Madrid, Spain. ferminsg@usal.es.; Centro en Red de Medicina Regenerativa y Terapia Celular de Castilla y León, Salamanca, Spain. ferminsg@usal.es.

Publikováno v: Stem cell research & therapy [Stem Cell Res Ther] 2021 Dec 07; Vol. 12 (1), pp. 601. Date of Electronic Publication: 2021 Dec 07.

Zobrazit plný text záznamu

Vybrat výsledek číslo 9 9

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vybrat výsledek číslo 10 10

Akademický článek

Optimisation of mesenchymal stromal cells karyotyping analysis: implications for clinical use.